FDA Approves Nivolumab with Ipilimumab for Unresectable or Metastatic MSI-H or dMMR Colorectal Cancer By Ogkologos - May 9, 2025 169 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the CHECKMATE-8HW study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Gemcitabine Intravesical System for Non-Muscle Invasive Bladder Cancer ESMO Calls for Robust EU Taxation of Tobacco Products, Aiming to Prevent Cancers Attributable to Tobacco Use EMA Recommends Granting a Marketing Authorisation for Biosimilar Pegfilgrastim MOST POPULAR Joining the dots: How our new research data strategy will unlock... July 7, 2022 Adding Pembrolizumab to Chemotherapy with or without Bevacizumab Improves Overall Survival... January 9, 2024 First-Line Treatment with Encorafenib Plus Cetuximab Plus mFOLFOX6 Significantly Improves ORR... February 17, 2025 ESMO Targeted Anticancer Therapies Congress 2025, Paris, France, 3-5 March February 24, 2025 Load more HOT NEWS Deaths from Metastatic Melanoma Drop Substantially in the United States FDA Approves Darolutamide for Metastatic Castration-Sensitive Prostate Cancer Seven Extra Years Qué debe saber sobre las pruebas de ADN en el hogar...
